Dianthus Therapeutics (DNTH) has released an update to notify the public and investors about an entry into a material definitive agreement.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Dianthus Therapeutics, Inc. has entered into a Securities Purchase Agreement for a private placement with investors, expecting to close the deal on January 24, 2024, involving the sale of over 14.5 million common shares and pre-funded warrants to purchase additional shares, totaling approximately $230 million. The company also signed a Registration Rights Agreement, committing to register the resale of the shares and warrants, with specific filing and effectiveness deadlines, and agreed to indemnity provisions. The securities are being sold without registration under the Securities Act, based on certain exemptions and representations by the purchasers, and are not to be sold without registration or exemption. Placement agents have been engaged with agreed compensation.
For further insights into DNTH stock, check out TipRanks’ Stock Analysis page.